News in brief
Asahi Glass consolidates bio-CDMO acquisitions under AGC Biologics brand
Over the past 18 months, Japanese glass solution provider AGC Asahi Glass has become a major biologics contract development and manufacturing organisation (CDMO) through the acquisitions of Biomeva GmbH and CMC Biologics.
In total the firm offers 44,000L of microbial and mammalian biomanufacturing capacity through these acquisitions from six facilities in the US, Denmark, Germany and Japan.
As such, the firm has opted to consolidate the two acquisitions under a single brand, AGC Biologics, and has appointed former CMC Biologics head Gustavo Mahler as president and CEO of the combined entity.
“With our proven track record, I believe that we will clearly pave the way to a successful future, providing our clients solutions to their greatest development and manufacturing challenges, and enabling the delivery of breakthrough treatments to patients across the globe,” Mahler said.